| "A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack [THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death] " |
Completed |
Ticagrelor |
3 |
D5134C00003 |
KFMC |
| A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3) |
Ongoing |
Ticagrelor |
3 |
D5136C00009 |
KFMC |
| A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. |
Terminated |
Macitentan (ACT-064992, Opsumit ®) |
3 |
67896062CTP3001 |
King Fahad Medical City (Riyadh),King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity of Arabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56 Years and Above in Saudi Arabia" |
Completed |
Meningococcal Conjugate Vaccine (MenACWY-CRM) (Aramen) |
3b |
ARA/001/16 |
KKUH |
| A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age |
Rejected |
Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612 |
3b |
114858 |
KFMC |
| A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART) |
Terminated |
Lutropin alfa |
3b |
EMR200061_506 |
KAUH-J |
| A Phase III, Randomized, doublE-blind, placebo-controlled trial to evaluate Immunogenicity and Safety of the Gam-COVID-Vac combined vector vaccine in prophylactic Treatment for SARS-СoV-2 infection in Saudi Arabia |
Completed |
Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection. |
3 |
RC20/497/R |
King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer |
Ongoing |
DOCETAXEL Paclitaxel TAMOXIFEN Letrozole |
3 |
S1007 |
KFSH & RC-R |
| "A Phase III, Open-label, Randomized Study To Evaluate The Efficacy And Safety of Adjuvant Alectinib Versus Adjuvant Platinum-based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors≥4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer " |
Completed |
ALECTINIB |
3 |
BO40336 |
KFSH&RC-R |
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk |
Completed |
BI 10773 |
3 |
1245.25 |
KFMC |
